Laboratory Products
Consistent and Economical Simulated Whole Blood Controls
May 06 2013
Providing cost effective, dependable quality control materials for ABO, and Rh antibody screening standardisation in automated blood grouping methods, Alpha Laboratories is proud to introduce the new ALBAcheck® DUO simulated whole blood controls. With twice the stability of standard controls and a higher useable sera volume, ALBAcheck DUO gives you more tests for your money.
Produced by leading manufacturer, Alba Bioscience, they have a consistent phenotype enabling definition of results and eliminating the need for repeated instrument set up and re-confirmation between control batches. The controls are manufactured to mimic patient samples. Vial 1 contains a simulated whole blood sample of A2B RhD negative (rr) cells with an Anti-D (0.1 IU/mL). Vial 2 contains a simulated whole blood sample of O RhD positive (R1R1) cells with Anti-A, Anti-B and an Anti-c.
Supplied as 6 ml of 15% cell suspensions, each ALBAcheck control vial contains 5.1 ml of sera. Other controls are typically supplied in 5 ml, 33% suspensions, providing only 3.35 ml usable sera volume. So, with ALBAcheck you get more tests per vial.
The impressive 14 day open vial stability offers double the shelf life of other controls, which typically only exhibit a 7 day stability. Since ALBAcheck DUO contains two vials of each control, you only need one kit per month, making it both convenient and space saving.
ALBAcheck® DUO is a very affordable control solution that meets the BCSH and transfusion guidelines for controlling ABO and Rh testing for both donors and patients.
Digital Edition
International Labmate 49.6 - Sept 2024
September 2024
Chromatography Articles - HPLC gradient validation using non-invasive flowmeters Mass Spectrometry & Spectroscopy Articles - From R&D to QC, making NMR accessible for everyone: Putting NMR...
View all digital editions
Events
Sep 29 2024 Singapore
Oct 06 2024 Liverpool, UK
Oct 08 2024 Gothenburg, Sweden
Oct 09 2024 Birmingham, UK
Oct 09 2024 NEC, Birmingham, UK